Peptide-based Infection Therapeutics Market

Peptide-based Infection Therapeutics Market Study by Telaprevir and Boceprevir Drugs from 2023 to 2033

Analysis of Peptide-based Infection Therapeutics Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Peptide-based Infection Therapeutics Market Outlook (2023 to 2033)

The global peptide-based infection therapeutics market stands at a valuation of US$ 1.98 billion in 2023 and is predicted to amass a revenue of US$ 4.4 billion by the end of 2033. Global demand for peptide-based infection therapeutics is forecasted to increase at a high CAGR of 8.3% over the next ten years.

Extensive use of antibiotic drugs had led to an increased incidence of antibiotic resistance among the general population, which has made them more prone to contracting infectious diseases. Increasing prevalence of deadly infectious diseases in the past few years has resulted in high demand for therapeutics and treatments to combat these infectious ailments.

Peptide-based therapeutics are capable of overcoming antibiotic resistance and have also proven their efficacy in the treatment of chronic ailments such as cancers. Peptides are safe and stable, and can also be designed for selective action, which makes them a popular choice in this emerging world of personalised medicine.

Peptide-based vaccines have been successful in fending off various infectious diseases and this is also projected to bolster peptide-based infection therapeutics market development in the future. Growing adoption of peptide-based cancer therapeutics, peptide-based cardiovascular therapeutics, and peptide-based metabolic disorder therapeutics is also expected to have a positive impact on shipments of peptide-based infection therapeutics in the long run.

Growing investments in R&D, increasing awareness regarding preventive healthcare, high frequency of infectious disease outbreaks, rising disposable income, growing focus on healthcare infrastructure development, and adoption of advanced healthcare technologies are other prospects that are slated to boost the demand for peptide-based infection therapeutics in the future.

However, the high costs associated with alternative peptide manufacturing techniques to avoid degradation could prove to be a major restraint for overall market evolution over the coming years.

Report Attributes


Peptide-based Infection Therapeutics Market Size (2023)

US$ 1.98 Billion

Projected Market Value (2033F)

US$ 4.4 Billion

Global Market Growth Rate (2023 to 2033)

8.3% CAGR

Online Pharmacies Segment Growth Rate (2023 to 2033)


Asia Pacific Market Growth Rate (2023 to 2033)

8.5% CAGR

Key Companies Profiled

  • Eli Lilly Company
  • Vertex Pharmaceuticals Incorporated
  • Dr. Reddy’s Laboratories Ltd.
  • CoredentPharma International
  • Merck & Co. Inc.
  • AmbioPharm Inc.
  • GenScript
  • Sun Pharmaceutical Industries Ltd.
  • Parchem Fine & Specialty Chemicals
  • Bharat Biotech

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Which Factors Will Usher Peptide-based Infection Therapeutics Market Development?

“Frequent Outbreaks of Infectious Diseases”

Several infectious disease outbreaks have been recorded in the past couple of decades and the frequency of these outbreaks is just increasing and their effect has now reached global pandemic levels as well. Swine flu, coronavirus, salmonella, and tuberculosis are some of the most common and popular infectious diseases currently affecting the global population at scale.

The advent of the COVID-19 pandemic in 2020 has revealed the full potential of what damage an infectious outbreak could do to human civilization and this has resulted in increased investments in research on infectious diseases and their treatments.

Peptide-based therapeutics and therapies are being extensively utilized in the treatment of several diseases and this trend is projected to boost their demand for infectious diseases as well. Governments are launching supportive initiatives to urge biotechnology and pharmaceutical companies to develop novel drugs and treatments for infectious diseases that are becoming increasingly unpredictable.

“Increasing Number of Pipeline Drugs”

Research and development in the pharmaceutical industry is continually peaking with more companies wanting to invest in the discovery of novel drugs and therapeutics to treat different diseases. Supportive government initiatives and the increasing number of research grants being awarded are other factors that are pumping more capital into the healthcare R&D sector. The aforementioned factors have resulted in a huge drug pipeline that is just expanding with more companies broadening their research scope to incorporate more diseases.

Peptide-based infection therapeutics market growth forecast by Fact.MR

Which New Companies Should Established Market Players Watch Out For?

“Peptilogics & Mytide Therapeutics Transforming Peptide Therapeutics Industry”

Upcoming peptide-based infection therapeutics companies are revolutionizing the marketplace with their novel offerings and are solely focusing on research and development of innovative technologies that could help treat several infectious diseases.

  • Mytide Therapeutics, is a biotechnology start-up based in Boston, United States that is focusing on accelerating peptide therapeutics research and development process to unlock its full potential. The company offers its disruptive manufacturing and R&D platform for companies invested in the development of peptide therapeutics.
  • In January 2022, Peptilogics, a start-up based in Pittsburgh, United States announced that it had received FDA clearance for Phase 1b clinical trials for its signature peptide therapeutic product PLG0206 that was focused on treating periprosthetic joint infections, a common phenomenon affecting people after having joint replacement surgeries.

This latest peptide-based infection therapeutics market research report by Fact.MR, a market research and competitive intelligence provider, gives a comprehensive account of how start-ups are impacting aspects such as pricing trends, product standards, global demand, and local supply trends to offer a comprehensive understanding of the current and forecasted market scenario.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Country-wise Insights

Why are Japan & Korea Considered Opportune Markets?

“Increasing Healthcare Expenditure and Growing Geriatric Population Offering Lucrative Business Scope”

The increasing frequency of infectious disease outbreaks has put people across the world at risk and this has resulted in high demand for preventive healthcare solutions, a trend that is also rife in Asian countries such as Japan, Korea, and India. Governments of Japan and Korea are investing in the expansion of their healthcare infrastructure to provide the best medical services and solutions for their people, which is expected to uplift peptide-based infection therapeutics demand in these Asian countries.

Increasing awareness regarding infectious ailments, growing per capita disposable income, rising availability of peptide therapeutics and peptide therapies, and a growing senescent population are other leading prospects that could augment sales of peptide-based infection therapeutics in Japan and Korea through 2033. Growing acceptance of advanced medical treatments in the aforementioned countries is also expected to offer new opportunities for peptide-based infection therapeutics manufacturers.

Which Countries in Europe are Remunerative Markets for Peptide-based Infection Therapeutics?

“United Kingdom & Germany to Lead Demand for Peptide-based Infection Therapeutics”

Increasing availability of peptide therapeutics in European countries such as Germany and the United Kingdom is projected to primarily bolster peptide-based infection therapeutics sales over the coming years. The growing use of peptide-based therapies for the treatment of various chronic disorders and increasing healthcare expenditure are expected to open up new avenues of opportunity for incoming peptide-based infection therapeutics companies as well as established market players.

Expanding aging population, supportive government initiatives, high demand for preventive medication, and expiration of patents for popular medications are other aspects that could favor peptide-based infection therapeutics market potential in most European countries over the next ten years. Growing investments in research are also projected to supplement market growth in Europe.

How Will Peptide-based Infection Therapeutics Demand Fare in the United States?

“High Investments in Healthcare R&D Driving Peptide-based Infection Therapeutics Shipments”

The developed healthcare infrastructure of the United States and supportive government initiatives to bolster research and development of novel healthcare technologies are anticipated to provide a highly remunerative setting for peptide-based infection therapeutics suppliers over the coming years. Increasing awareness regarding preventive healthcare and the growing prevalence of infectious disease outbreaks are other prospects that could boost sales of peptide-based infection therapeutics in the future.

The presence of key pharmaceutical manufacturing companies, high patient spending potential, rapid adoption of novel healthcare technologies, and increasing case count for diseases such as tuberculosis, salmonella, etc. could also potentially aid market development through 2033.

  • As per data provided by the Centers for Disease Control and Prevention (CDC), 8916 and 58371 new cases of tuberculosis and salmonella were recorded respectively in 2019 in the United States.

Category-wise Insights

Which Distribution Channel Leads Peptide-based Infection Therapeutics Sales?

“Hospital Pharmacies Holding Dominant Market Share”

Based on distribution channel, the peptide-based infection therapeutics market is segmented into hospital pharmacies, retail pharmacies, drug stores, and online pharmacies.

The increasing rate of hospitalization and growing investments in healthcare infrastructure development are factors that bolster peptide-based infection therapeutics demand in hospital pharmacies and help them maintain a significant share in the global landscape.

Meanwhile, shipments of peptide-based infection therapeutics through online pharmacies are slated to rise at a phenomenal pace of around 9% CAGR over the next ten years. Demand through online pharmacies is crucially dependent on increasing digitization and the growing popularity of e-Commerce across the world.

Retail pharmacies are also anticipated to witness a hike in demand for peptide-based infection therapeutics from 2023 to 2033 at a CAGR of around 8%. The growing development of retail infrastructure in developing economies is anticipated to be a prime aspect driving peptide-based infection therapeutics sales through retail pharmacies in the future.

Competitive Landscape

Prime peptide-based infection therapeutics suppliers are investing in the research and development of novel products to advance their business potential and strengthen their market presence on a global level. Some of the key peptide-based infection therapeutics manufacturers mentioned in this report are Vertex Pharmaceuticals Incorporated, Parchem Fine & Specialty Chemicals, and Merck & Co. Inc., among others.

All the new developments by established and new peptide-based infection therapeutics companies have been extensively listed in this Fact.MR research report.

Segmentation of Peptide-based Infection Therapeutics Industry Research

  • By Drug :

    • Telaprevir
    • Boceprevir
  • By Distribution Channel :

    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region :

    • North America
    • Latin America
    • Europe
    • APAC
    • MEA

- FAQs -

What is the current size of the peptide-based infection therapeutics market?

The global peptide-based infection therapeutics market accounts for US$ 1.98 billion value in 2023.

How big will the market for peptide-based infection therapeutics be by 2033?

Shipments of peptide-based infection therapeutics are slated to amass a revenue of US$ 4.4 billion by 2033-end.

What is the projected market expansion rate?

Over the next ten years, peptide-based infection therapeutics demand is estimated to increase at 8.3% CAGR.

Which distribution channel will account for higher sales?

Peptide-based infection therapeutics sales through online pharmacies are forecasted to rise at 9% CAGR through 2033.

Who are the key peptide-based infection therapeutics providers?

CoredentPharma International, Merck & Co. Inc., AmbioPharm Inc., and GenScript are prime companies in this industry.

Peptide-based Infection Therapeutics Market

Schedule a Call